|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
Datamonitor, June 2005, Pages: 205
The current ADHD market has long been saturated with traditional methylphenidate and amphetamine based drugs, with the only innovations being the development of extended release versions. However, the recent launch of Strattera (atomoxetine) has already shattered the traditional approach to drug therapy, opening the door for the uptake of new novel drug therapies.
Report Scope
Overview of the epidemiology, diagnosis and management of ADHD across the seven major pharmaceutical markets
Examination of the ADHD pipeline with in-depth clinical and commercial profiles of late-stage candidates, incorporating our opinion
Seven market sales forecasts, commercial potential and research/clinical/commercial assessment of late-stage products to 2015
Insight and commentary from qualitative interviews with ADHD opinion leaders in the US and Europe
Report Highlights
The current global ADHD market is worth $2.7bn and is expected to reach $3.4bn by 2015, driven primarily by the launch of pipeline drugs and the continued growth of Strattera.
Innovation is key - manufacturers can no longer expect significant returns on standard extended release formulations. The current pipeline offers drugs with novel delivery mechanisms; improved durations of action and anti-abuse profiles, which will help differentiate these pipeline drugs from the current established ADHD therapies.
Although ADHD drugs have demonstrated significant efficacy in improving the three main symptoms of ADHD - inattention, hyperactivity and impulsivity - none have shown efficacy in treating the cognitive deficits of ADHD.
Reasons to Purchase
Understand unmet needs in the ADHD market based on opinion leader comments regarding both currently marketed and pipeline products
Benchmark key late-stage ADHD compounds against current market leaders
Assess the global sales forecasts of late-stage pipeline drugs for ADHD and examine their clinical and commercial potential'
Customers who bought this item also bought
Commercial And Pipeline Insight: ADHD - Immature Adult Market Continues To Offer Greatest Commercial Potential
Adult ADHD - Strattera Grows Up
Commercial Insight: ADHD - Strattera Reigns Supreme as Branded Stimulants Slump
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
U.S. Attention Deficit Hyperactivity Disorder (ADHD) Markets
Adhd Market: Pestel Analysis and Scenario Based Forecasts
Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition
ADHD & Insomnia Treatments
The ADD and ADHD Cure: The Natural Way to Treat Hyperactivity and Refocus Your Child
US market size for attention deficit / hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, number of prescriptions and ADHD drug sales in US dollars for 1999 forecast to 2004, with breakdown of dollar sales, Rx numbers and
US market size for attention deficit hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, by number of ADHD prescriptions and by dollar value of ADHD pharmaceutical sales; breakout of percent market share, number of prescrip
Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment
|
|
|
|
